Inhibitor of apoptosis (IAP) proteins are frequently expressed at high levels in cancer cells and represent attractive therapeutic targets. We previously reported that the Smac (second mitochondria-derived activator of caspases) mimetic BV6, which antagonizes IAP proteins, sensitizes glioblastoma cells to temozolomide (TMZ)-induced cell death in a nuclear factor-κB (NF-κB)-dependent manner. However, BV6-induced NF-κB target genes responsible for this synergistic interaction have remained elusive. Using whole-genome gene expression profiling, we here identify BV6-stimulated, NF-κB-dependent transcriptional upregulation of interferon-β (IFNβ) and IFN-mediated proapoptotic signaling as critical events that mediate BV6/TMZ-induced apoptosis. Knockdown of IFNβ significantly rescues cells from BV6/TMZ-induced cell death. Similarly, silencing of the corresponding receptor IFNα/β receptor (IFNAR) confers a significant protection against apoptosis, demonstrating that IFNβ and IFN signaling are required for BV6/TMZ-mediated cell death. Moreover, BV6 and TMZ cooperate to transcriptionally upregulate the proapoptotic B-cell lymphoma 2 family proteins Bax (Bcl-2-associated X protein) or Puma (p53-upregulated modulator of apoptosis). Knockdown of Bax or Puma significantly decreases BV6/TMZ-induced apoptosis, showing that both proteins are necessary for apoptosis. By identifying IFNβ as a key mediator of BV6/TMZ-induced apoptosis, our study provides novel insights into the underlying molecular mechanisms of Smac mimetic-mediated chemosensitization with important implications for the development of novel treatment strategies for glioblastoma.
Glioblastoma is the most common primary malignant brain tumor and current treatment options include surgical resection, radiation and chemotherapy with the alkylating agent temozolomide (TMZ). 1 However, despite aggressive treatment regimens, the prognosis of patients suffering from glioblastoma is still very poor, 2 highlighting the high medical need for novel treatment strategies.
Evasion of programmed cell death is one of the hallmarks of human cancers 3 and promotes tumorigenesis as well as treatment resistance. 4 Apoptosis is a common form of programmed cell death that can be engaged via the intrinsic (mitochondrial) or extrinsic (death receptor) pathway. 5 Activation of the intrinsic pathway is controlled by pro-and antiapoptotic B-cell lymphoma 2 (Bcl-2) family protein, including Bcl-2 family proteins such as p53-upregulated modulator of apoptosis (Puma) or Bcl-2-associated X protein (Bax). Following engagement of the mitochondrial pathway, mitochondrial intermembrane space proteins are released into the cytosol, including second mitochondria-derived activator of caspases (Smac). 6 Smac binds to and neutralizes Inhibitor of Apoptosis (IAP) proteins, a family of antiapoptotic proteins, thereby promoting activation of caspases and apoptosis. 7 In addition, binding of Smac to IAP proteins that harbor a Really Interesting New Gene (RING) domain with E3 ligase activity triggers their autoubiquitination and proteasomal degradation, which in turn leads to stabilization of nuclear factor-κB (NF-κB)-inducing kinase (NIK) and activation of noncanonical NF-κB signaling. 8, 9 IAP proteins are expressed at high levels in various cancers and represent attractive targets for therapeutic intervention. 7 BV6 is a synthetically designed Smac mimetic that mimics the N-terminal part of endogenous Smac protein. 8 We previously reported that Smac mimetics such as BV6 sensitize glioblastoma cells to chemotherapy-or γ-irradiation-induced apoptosis in an NF-κB-dependent manner. [10] [11] [12] Although BV6-stimulated NF-κB activation was demonstrated to be critically required for Smac mimetic-mediated sensitization of glioblastoma cells towards TMZ, the proapoptotic NF-κB-regulated target genes that mediate this chemosensitization have so far remained elusive. 12 While tumor necrosis factor α (TNFα), a prototypic NF-κB target gene, was shown to mediate apoptosis via an autocrine/paracrine loop upon treatment with Smac mimetic alone 8, 9, 13 or in combination with anticancer drugs in different carcinoma cell lines, 14 TNFα was found to be largely dispensable for BV6/TMZ-induced apoptosis in glioblastoma cells. 12 In the present study, we therefore aimed at discovering novel NF-κB-dependent factors that are required for the cooperative anticancer activity of BV6 and TMZ, the prototypic chemotherapeutic agent used for the treatment of glioblastoma.
Results
BV6/TMZ cotreatment upregulates IFN-responsive genes before cell death induction. Initially, we assessed cell death upon treatment with the chemotherapeutic agent TMZ and the Smac mimetic BV6 using the glioblastoma cell lines A172 and T98G to confirm that Smac mimetic enhances TMZ-induced apoptosis, as we reported previously. 12 Indeed, determination of DNA fragmentation as a marker of apoptosis demonstrated that BV6 sensitizes glioblastoma cells to TMZinduced apoptotic cell death ( Figure 1a and Supplementary Figure 1 ). As Smac mimetics have been described to activate NF-κB signaling, we stably overexpressed dominant-negative IκBα-superrepressor (IκBα-SR) to block NF-κB signaling 15 ( Figure 1c) . Remarkably, inhibition of NF-κB by IκBα-SR almost completely rescued cells from BV6/TMZ-induced apoptosis (Figure 1b) , underlining the proapoptotic role of NF-κB signaling in this context. To further investigate which BV6-induced NF-κB target genes are responsible for proapoptotic signaling upon BV6/TMZ cotreatment, we performed whole-genome expression profiling using an expression bead chip hybridization assay. Whole-genome expression data were ranked according to fold upregulation comparing A172 glioblastoma cells expressing empty vector (EV) with and without BV6/TMZ treatment. Expression data showing upregulation in A172 glioblastoma cells expressing IκBα-SR served as control to identify background expression of non-NF-κB-regulated genes. BV6-treated cells showed a similar expression pattern as BV6/TMZ cotreated cells (data not shown). Interestingly, gene set enrichment analysis (GSEA) revealed upregulation of interferon (IFN)-responsive genes after BV6/TMZ treatment (Table 1 and Supplementary Figure  2 ). These results demonstrate that BV6/TMZ treatment upregulates IFN-responsive genes in an NF-κB-dependent manner. (Figure 2a ). In addition, BV6-stimulated transcriptional upregulation of IFNβ was inhibited in IκBα-SR-overexpressing cells (Figure 2a) , demonstrating that it occurs in an NF-κB-dependent manner. In contrast to IFNβ, IFNα mRNA expression levels remained largely unchanged upon treatment with BV6 and/or TMZ (Figure 2b ).
To explore whether IFNβ acts in concert with TMZ to cause cell death, we treated glioblastoma cells with IFNβ alone and in combination with TMZ. Intriguingly, IFNβ significantly increased TMZ-induced cell death in A172 and T98G cells compared to treatment with either agent alone ( Figure 2c ). In addition to IFNβ, IFNα significantly enhanced TMZ-induced cell death in glioblastoma cells (Supplementary Figure 3) . This set of experiments demonstrates that BV6/TMZ induces upregulation of IFNβ in an NF-κB-dependent manner and that IFNβ and TMZ cooperate to induce apoptosis in glioblastoma cells.
IFNβ is required for BV6/TMZ-induced apoptosis. To examine whether IFNβ is required for BV6/TMZ-induced cell death, we created IFNβ-knockdown cells (Figure 3a) . Remarkably, silencing of IFNβ significantly inhibited BV6/TMZ-mediated cell death (Figure 3b ). Type I IFNs such as IFNα and IFNβ bind to a transmembrane receptor termed IFNα/β receptor (IFNAR) and thereby induce transcriptional activation of IFN-stimulated genes (ISGs). 18 To examine whether IFNAR signaling is involved in BV6/TMZ-induced cell death, we generated IFNAR1-knockdown cells (Figure 3c ). Silencing of IFNAR1 significantly reduced BV6/TMZ-mediated cell death (Figure 3d ). In addition, knockdown of IFNAR1 rescued cells from IFNβ/TMZ-induced cell death (Figure 3e ). Taken together, this set of experiments demonstrates that IFNβ has an important role in mediating BV6/TMZ-induced cell death.
BV6/TMZ-induced apoptosis is mediated by cooperative upregulation of Puma and Bax. ISGs have been described to mediate IFN-induced apoptosis via upregulation of proapoptotic proteins, including proteins of the mitochondrialdependent cell death pathway. 19 To link BV6/TMZ-mediated activation of IFN signaling to activation of the mitochondrial apoptotic pathway, we analyzed the expression levels of various proapoptotic Bcl Figures 4d and f) . These results demonstrate that Puma and Bax contribute to BV6/TMZ-induced cell death.
Discussion
We previously reported NF-κB-dependent sensitization of glioblastoma cells to TMZ-induced apoptosis by the Smac mimetic BV6 as a novel approach to enhance the efficacy of conventional chemotherapy in glioblastoma. 12 However, the proapoptotic NF-κB target genes mediating this synergistic interaction have so far remained elusive, as autocrine/ paracrine TNFα/TNF receptor 1 (TNFR1) signaling turned out to be largely dispensable. 12 In the present study, we identify Smac mimetic-stimulated, NF-κB-dependent upregulation of IFNβ and IFN-mediated proapoptotic signaling as critical events that mediate BV6/TMZ-induced apoptosis (Supplementary Figure 5 ). This conclusion is based on the following lines of evidence:
First, treatment with BV6 alone or in combination with TMZ triggers transcriptional upregulation of IFNβ in an NF-κB-dependent manner, as this increase in IFNβ mRNA levels is blocked by IκBα-SR-mediated inhibition of NF-κB. In addition, gene expression profiling shows an NF-κB-dependent upregulation of ISGs upon BV6/TMZ treatment. Second, BV6-induced upregulation of IFNβ-and IFNmediated signaling are required for the induction of apoptosis, as genetic silencing of either IFNβ or its corresponding receptor IFNAR significantly reduces BV6/TMZ-induced apoptosis. The notion that BV6-stimulated upregulation of In the present study, we identify IFNβ as a key mediator of BV6/TMZ-induced cell death that is transcriptionally upregulated in an NF-κB-dependent manner upon treatment with the Smac mimetic BV6. Whether or not this increase in IFNβ is directly mediated via NF-κB transcription factors 20 or indirectly mediated via NF-κB-dependent upregulation or activation of transcription factors regulating IFNβ 21 remains to be investigated in future studies. It is interesting to note that type I IFNs such as IFNβ or IFNα have recently been reported to act in concert with TMZ to trigger cell death in glioblastoma cells, although the mechanisms responsible for this cooperative effect have so far remained elusive. 16, 17 In contrast to the critical role of IFNβ for BV6/TMZ-induced apoptosis that we discovered in the current study, we previously reported that TNFα, another prototypic NF-κB target gene, is largely dispensable for BV6/TMZ-induced apoptosis, as addition of the TNFα-blocking antibody Enbrel or TNFR1 knockdown failed to rescue apoptosis upon combination treatment. 12 Although our study demonstrates for the first time that the Smac mimetic BV6 can transcriptionally induce IFNβ as an important mediator of Smac mimetic-conferred chemosensitization in glioblastoma cells, IFN signaling has been implicated in the past to foster cell death by Smac mimetics. For example, we recently reported that BV6 synergizes with IFNα to trigger apoptosis in acute myeloid leukemia cells. 22 Of note, BV6 was found in the present study to transcriptionally upregulate IFNβ, but not IFNα in glioblastoma cells, pointing to distinct roles of type I IFNs in this context. Moreover, we identified IFN regulatory factor 1 (IRF1) as a novel dual regulator of Smac mimetic BV6-induced apoptosis and proinflammatory cytokine secretion with impact on the immune response. 23, 24 Furthermore, Smac mimetics have been described to act in concert with innate immune stimuli such as oncolytic viruses and adjuvants, which stimulate a cytokine storm of TNFα, TNF-related apoptosis-inducing ligand and IFNβ, to trigger cancer cell death. Induction of cell death by IFNβ has been described to involve ISGs. 19 However, little is yet known about which ISGs mediate these apoptotic functions. Transcription factors regulated via IFNs such as IRF1 and IRF3 have been reported to promote upregulation or activation of Puma and Bax. 26, 27 Puma and Bax were also described as DNA damage-induced target genes that are upregulated by TMZ treatment. 28 Consistently, we show in the present study that IFNβ and TMZ cooperate to upregulate Puma and Bax, which both contribute to BV6/TMZ-induced apoptosis, as genetic silencing of either Bax or Puma, two Bcl-2 family proteins known to promote mitochondrial apoptosis, rescues glioblastoma cells from cell death. In line with these findings, we previously reported that cotreatment with BV6/TMZ activates the mitochondrial pathway of apoptosis as demonstrated by the loss of mitochondrial membrane potential and cytochrome C release. 12 Furthermore, context-specific settings have an impact on the regulation of signaling pathways and cellular functions by Smac mimetics, depending, for example, on additional cytotoxic stimuli and/or cell types. We demonstrated that Smac mimetics can exert non-apoptotic functions and can stimulate migration and invasion of glioblastoma cells via activation of NF-κB and TNFα/TNFR1 autocrine/paracrine signaling. 23, 24 In glioblastoma cancer stem-like cells, Smac mimetics at non-toxic concentrations can promote astrocytic differentiation by activating NF-κB. 29 Smac mimetics are currently evaluated in early clinical trials. 30 By identifying IFNβ as a novel Smac mimetic-induced and NF-κB-mediated target gene that has an important role in mediating chemosensitization by Smac mimetic, our findings provide novel mechanistic insights into this combination regimen. Additionally, our present study emphasizes that Smac mimetics are effective sensitizers for TMZ-induced apoptosis in glioblastoma cells with implications for the development of experimental treatment approaches.
Materials and Methods
Cell culture and chemicals. The human glioblastoma cell lines A172 and T98G were obtained from the American Type Culture Collection (Manassas, VA, USA) and maintained in DMEM medium (Invitrogen, Karlsruhe, Germany) supplemented with 1% penicillin/streptomycin, 1% sodium pyruvate and 10% fetal calf serum (Invitrogen). For experiments, cells were seeded at 5 × 10 3 cells/cm 2 . Smac mimetic BV6, which neutralizes XIAP, cIAP1 and cIAP2, 8 was kindly provided by Genentech Inc. (South San Francisco, CA, USA), TMZ was purchased from Sigma (Taufkirchen, Germany) and recombinant human IFNα and IFNβ from Biochrom (Berlin, Germany). All chemicals were obtained from Sigma, unless indicated otherwise.
Determination of apoptosis. Apoptosis was assessed by flow cytometric analysis (FACSCanto II; BD Biosciences, Heidelberg, Germany) of DNA fragmentation of propidium iodide (PI)-stained nuclei as described previously. 31 Western blotting. Western blot analysis was performed as described previously 12 using the following antibodies: anti-IκBα (Cell Signaling, Beverly, MA, USA), anti-Bax (BD Biosciences), anti-Puma (Cell Signaling) and anti-β-actin (Sigma). Donkey anti-mouse IgG or donkey anti-rabbit IgG labeled with IRDye infrared dyes were used for fluorescence detection at 680-800 nm (LI-COR Biotechnology, Bad Homburg, Germany).
Whole-genome gene expression array and GSEA. Gene expression profiling was performed as described previously 32 using Illumina Whole-Genome Expression Beadchips Human HT12v4 (Illumina, San Diego, CA, USA). Expression data were ranked according to fold upregulation comparing A172 glioblastoma cells expressing EV with and without BV6/TMZ treatment. Expression data showing upregulation with and without BV6/TMZ treatment in A172 glioblastoma cells expressing IκBα-SR served as control to identify background expression of non-NF-κB-regulated genes. GSEA was performed using software provided by the Broad Institute website (http://www.broadinstitute. org/gsea/index.jsp). 33 Transduction and siRNA transfection. Overexpression of the dominantnegative IκBα-SR was performed by retroviral transduction as described previously. 15 For transient knockdown by siRNA, cells were transfected with 20 nM Silencer Select siRNA (Invitrogen) control siRNA (no. 4390844) or targeting siRNAs (s7188 and s7189 for IFNβ, s782 and s784 for IFNAR1, s1888 and s1890 for Bax, s25840 and s25842 for Puma) using Neon Transfection System (Invitrogen) according to the manufacturer's instructions.
qRT-PCR analysis. Total RNA extraction and qRT-PCR analysis was performed as described previously 32 using 7900HT Fast Real-Time PCR System (Applied Biosystems, Darmstadt, Germany). The following primers were used: 28 S (forward, 5′-TTGAAAATCCGGGGGAGAG-3′; reverse, 5′-ACATTGTTCCAACA TGCCAG-3′), IFNAR1 (forward, 5′-TCCAGTACATTGTATAAAGACCACAGT-3′; reverse, 5′-GTTCTGATTTTGGACACTGACTTC-3′), Puma (forward, 5′-GACCTC AACGCACAGTACGA-3′; reverse, 5′-GAGATTGTACAGGACCCTCCA-3′), Bax (forward, 5′-AGCAAACTGGTGCTCAAGG-3′; reverse, 5′-TCTTGGATCCAGCC CAAC-3′), Bak (forward, 5′-CCTGCCCTCTGCTTCTGA-3′; reverse, 5′-CTGCTGA TGGCGGTAAAAA-3′), Noxa (forward, 5′-GGAGATGCCTGGGAAGAAG-3′; reverse, 5′-CCTGAGTTGAGTAGCACACTCG-3′), Bid (forward, 5′-TGCAGCTCA GGAACACCA-3′; reverse, 5′-TCTCCATGTCTCTAGGGTAGGC-3′), Bim (forward, 5′-CATCGCGGTATTCGGTTC-3′; reverse, 5′-GCTTTGCCATTTGGTCTTTTT-3′), Bmf (forward, 5′-GAGACTCTCTCCTGGAGTCACC-3′; reverse, 5′-CTGGTTGGA ACACATCATCCT-3′). Melting curves were plotted to verify the specificity of the amplified products. IFNα and IFNβ mRNA levels were assessed by TaqMan Gene Expression Assay (Life Technologies, Darmstadt, Germany; IFNαHs01077958_s1, IFNβHs00855471_g1) according to the manufacturer's protocol. The relative expression of the target gene transcript and reference gene transcript was calculated as ΔΔC t . 
